Breast Cancer Clinical Trials in Germantown, Tennessee

6 studies are recruiting for breast cancer in Germantown, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

   This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   West Cancer Center, Germantown, Tennessee

   Locations

   241 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06790693 on ClinicalTrials.gov

2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   The West Clinic - Wolf River, Germantown, Tennessee

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

3. A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

   This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   West Cancer Center, Germantown, Tennessee

   Locations

   34 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07054190 on ClinicalTrials.gov

4. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

   Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherap…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee

   Locations

   65 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05768139 on ClinicalTrials.gov

5. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee

   Locations

   202 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

6. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

   The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

   Stage

   Not phased

   Ages

   18 and older

   Site

   West Cancer Center, Germantown, Tennessee

   Locations

   134 in total

   Run by

   Agendia

   See if you can join NCT03053193 on ClinicalTrials.gov